-
Lipocine Gets A Boost After News From The FDA
Monday, October 17, 2016 - 9:12am | 355Read More...Lipocine Inc (NASDAQ: LPCN) is a nano-cap specialty pharmaceutical company whose lead product candidate is an oral testosterone replacement therapy called LPCN 1021. Shares of Lipocine were trading higher by more than 12 percent ahead of Monday's opening bell after the company announced the...
-
McKesson Announces Acquisitions That Expands Its Oncology Expertise
Thursday, February 25, 2016 - 1:46pm | 254Read More...McKesson Corporation (NYSE: MCK) announced on Thursday two separate acquisitions to increase its specialty pharmaceutical distribution scale and oncology-focused pharmacy offerings, solutions for manufacturers and payers, and scope of community-based oncology and practice management services....
-
Here's Why Carbylan Therapeutics Lost Nearly Half Of Its Value
Tuesday, February 2, 2016 - 9:22am | 296Read More...Shares of Carbylan Therapeutics Inc (NASDAQ: CBYL), a nano-cap clinical-stage specialty pharmaceutical company, plunged nearly 50 percent after the company announced top-line results from a Phase 3 trial, COR1.1. COR1.1 was a 560 patient, international, multi-center and randomized double-blind...
